RankAlpha logo
Back to Rankings

ALNY

AlnylamB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Q2 TTR revenue reached $1.030 billion, up 89% year over year, and continued ATTR-CM diagnosis and treatment growth could support the launch despite the reset. The October ALN-HTT02 readout offers a separate, high-risk pipeline option.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29 · BMO.
What can break
ALN-HTT02 Phase 1 results may reveal safety, tolerability, or biological-activity limitations; clinical efficacy is not established. [#SEC-8K-2026-07-30]
Momentum
36
Value
60
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $230.00 · Bull $280.00 · Bear $165.00Analysis 2026-10-06; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-06 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $371.39
Why
Momentum36 · Δ7d +14.0
Value60 · Δ7d +0.1
Sentiment56 · Δ7d +4.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29 · BMO.
  • • Value remains the lead driver in the composite, 7D delta +0.1.

Contradictions & invalidation

  • • ALN-HTT02 Phase 1 results may reveal safety, tolerability, or biological-activity limitations; clinical efficacy is not established. [#SEC-8K-2026-07-30]
  • • Commercial growth depends on continued ATTR-CM diagnosis, treatment initiation, and competitive execution; the packet lacks current channel-level launch data.
  • • The TTR guidance reduction indicates that early second-line demand was less durable than previously expected.

Catalyst clock

2026-10-29 · BMO

ALN-HTT02 Phase 1 data at EHDN

Lead driver: Value · See fundamentals
Momentum
36
8% active weight
Current posture
7d trendImproving
Δ7d
+14.0
Δ21d
+16.4
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.7
Sentiment
56
45% active weight
Current posture
7d trendImproving
Δ7d
+4.6
Δ21d
-27.1
Why this grade

Composite grade B. Momentum 36.4 / Value 59.6 / Sentiment 56.4

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-06. Scenario method

B+
Bull case
25%
Probability
Target price
$280.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$230.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$165.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$29.98B
Beta
0.35
Shares Out
133.81M
P/E (TTM)
1738.9
P/S (TTM)
16.37
P/FCF (TTM)
237.43
Rev YoY
+66.9%
EPS YoY
-318.3%
Gross Margin
+79.7%
Op Margin
+20.8%
Net Debt
$60.31M
Current Ratio
3.05
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data